Adding immunotherapy improves survival rates in anal cancer
Treating advanced anal cancer patients with both immunotherapy and chemotherapy improved overall survival by an average of six months, according to a study led by The Royal Marsden NHS Foundation Trust.
Patients with advanced squamous cell anal carcinoma (SCAC) are usually treated with chemotherapy.
Results from the Phase III POD1UM-303/InterAACT2 trial, funded by Incyte, demonstrate that adding retifanlimab to chemotherapy resulted in a 37% reduction in the risk of cancer progression or death.
In May 2025, retifanlimab was granted approval from the US Food and Drug Administration (FDA) in combination with carboplatin and paclitaxel (platinum-based chemotherapy drugs) for adult patients with locally recurrent or metastatic SCAC.
The treatment was also approved for use on its own for adult patients with locally recurrent or metastatic SCAC, with disease progression or intolerance to platinum-based chemotherapy.
Regulatory review in the EU is ongoing with a regulatory submission in the UK to follow.
The POD1UM-303/InterAACT2 trial
In the trial, researchers found at an interim analysis that the patients who received retifanlimab in combination with chemotherapy saw an improvement in median overall survival compared to patients who received chemotherapy (29.2 months vs. 23 months).
Patients who received the retifanlimab and chemotherapy combination did not see their disease progress for an average of 9.3 months compared to 7.4 months for patients who received chemotherapy only.
The patients in the combination retifanlimab and chemotherapy group experienced improvements in the overall response rate (55.8% vs. 44.2%) and the duration of response doubled (14.0 months vs. 7.2 months) compared with the combination placebo and chemotherapy group.
New data at ASCO
Data presented at The American Society for Clinical Oncology (ASCO) 2025 demonstrated that patients who switched to retifanlimab after their cancer progressed had a slightly worse response to the treatment than those who received retifanlimab with chemotherapy from the start.
This patient group had a median overall survival of 29.2 months compared to 24.3 months for those who received retifanlimab after progression.
Retifanlimab combined with chemotherapy helped patients across all groups, even those with liver metastases and HPV or HIV infection.
Dr Sheela Rao, Consultant Medical Oncologist at The Royal Marsden, said: “SCAC is a disease with significant medical need and despite its increasing incidence, the rare condition often has a poor prognosis. Patients have been waiting a long time for new treatment options and have been receiving the same standard of care for decades.
“This trial is the first Phase III trial evaluating a checkpoint inhibitor for the treatment of patients with SCAC and I believe the positive results from the trial reinforce the promise of retifanlimab as a new treatment option for adults with inoperable locally recurrent or metastatic SCAC.”
Diana Spencer, Senior Digital Content Editor, DDW
